[
  {
    "ts": null,
    "headline": "Elon Musk Becomes First Person Worth $500 Billion, Tesla CEO's Wealth Is Now Larger Than Palantir, Alibaba",
    "summary": "Elon Musk has achieved yet another historic milestone, becoming the first person in history to be worth $500 billion, driven by Tesla Inc.'s (NASDAQ:TSLA) stock rally, SpaceX’s soaring valuations, and the growing value of his AI venture, xAI ...",
    "url": "https://finnhub.io/api/news?id=ae7f7686a96654803319fb3e0c4d1625a219fec80e90cc8dd2a1601575fc9c4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759429870,
      "headline": "Elon Musk Becomes First Person Worth $500 Billion, Tesla CEO's Wealth Is Now Larger Than Palantir, Alibaba",
      "id": 136959823,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Elon Musk has achieved yet another historic milestone, becoming the first person in history to be worth $500 billion, driven by Tesla Inc.'s (NASDAQ:TSLA) stock rally, SpaceX’s soaring valuations, and the growing value of his AI venture, xAI ...",
      "url": "https://finnhub.io/api/news?id=ae7f7686a96654803319fb3e0c4d1625a219fec80e90cc8dd2a1601575fc9c4b"
    }
  },
  {
    "ts": null,
    "headline": "USOP Names Johnson & Johnson Its Official Vendor for Total Joint Products",
    "summary": "U.S. Orthopaedic Partners (USOP) announced a strategic agreement today with Johnson & Johnson to make the medtech solutions giant its official vendor for total joint products. The agreement is projected to deliver immediate, meaningful value for the platform as it continues to elevate clinical quality and patient outcomes.",
    "url": "https://finnhub.io/api/news?id=163a0284d4d13e04a9b73b134fedb2daa954664e1a0a3de205c26a73cb856318",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759413060,
      "headline": "USOP Names Johnson & Johnson Its Official Vendor for Total Joint Products",
      "id": 136959966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "U.S. Orthopaedic Partners (USOP) announced a strategic agreement today with Johnson & Johnson to make the medtech solutions giant its official vendor for total joint products. The agreement is projected to deliver immediate, meaningful value for the platform as it continues to elevate clinical quality and patient outcomes.",
      "url": "https://finnhub.io/api/news?id=163a0284d4d13e04a9b73b134fedb2daa954664e1a0a3de205c26a73cb856318"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific aims for market leadership in electrophysiology",
    "summary": "The company has now treated 500,000 patients with its pulsed field ablation system, in a competitive category poised for growth.",
    "url": "https://finnhub.io/api/news?id=65b8340abb584682561280e86b85a5100a80cb20166a68ea8b0de0e348531c7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759403169,
      "headline": "Boston Scientific aims for market leadership in electrophysiology",
      "id": 136959967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The company has now treated 500,000 patients with its pulsed field ablation system, in a competitive category poised for growth.",
      "url": "https://finnhub.io/api/news?id=65b8340abb584682561280e86b85a5100a80cb20166a68ea8b0de0e348531c7c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Is Leading The Industry In Cancer Treatments, Says Jim Cramer",
    "summary": "We recently published 5 Stocks That Were On Jim Cramer’s Radar As He Discussed AI. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the most diversified healthcare companies in the world. The firm operates in the pharmaceutical, medical devices, and other industries. Cramer […]",
    "url": "https://finnhub.io/api/news?id=d0c816e095f26751096bf1d19a6989f0a42c2d8195125b397ed99e5b4a22d15b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759388914,
      "headline": "Johnson & Johnson (JNJ) Is Leading The Industry In Cancer Treatments, Says Jim Cramer",
      "id": 136955302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published 5 Stocks That Were On Jim Cramer’s Radar As He Discussed AI. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the most diversified healthcare companies in the world. The firm operates in the pharmaceutical, medical devices, and other industries. Cramer […]",
      "url": "https://finnhub.io/api/news?id=d0c816e095f26751096bf1d19a6989f0a42c2d8195125b397ed99e5b4a22d15b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Gains FDA Nod for TREMFYA Subcutaneous Therapy",
    "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the top picks for a retirement portfolio. On September 26, Johnson & Johnson (NYSE:JNJ) reported that the US FDA had approved a subcutaneous induction protocol of TREMFYA (guselkumab) for the treatment of individuals with moderate to severe active ulcerative colitis. With this approval, TREMFYA becomes the first IL-23 inhibitor […]",
    "url": "https://finnhub.io/api/news?id=acdae7b53aa7858d3c42e640d9f0771aa2505ae08ee60c838cc3649b68b5abf5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759388130,
      "headline": "Johnson & Johnson (JNJ) Gains FDA Nod for TREMFYA Subcutaneous Therapy",
      "id": 136955330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the top picks for a retirement portfolio. On September 26, Johnson & Johnson (NYSE:JNJ) reported that the US FDA had approved a subcutaneous induction protocol of TREMFYA (guselkumab) for the treatment of individuals with moderate to severe active ulcerative colitis. With this approval, TREMFYA becomes the first IL-23 inhibitor […]",
      "url": "https://finnhub.io/api/news?id=acdae7b53aa7858d3c42e640d9f0771aa2505ae08ee60c838cc3649b68b5abf5"
    }
  }
]